Publications by authors named "Rang-Ru Liu"
Article Synopsis
- This study aims to identify genetic variations that affect the response to metformin, a common diabetes medication, in Chinese patients with type 2 diabetes (T2D).
- Researchers analyzed 3739 genetic variants (SNPs) in a two-stage study involving 500 patients, finding 50 initially associated with drug response, with two SNPs successfully validated as significant.
- The identified SNPs, rs2727528 and rs1105842, are linked to a greater change in HbA levels in those treated with metformin, suggesting potential for personalized treatment strategies in diabetes management.
The dysfunction and mutual compensatory activation of RAF-MEK-ERK and PI3K-PDK1-AKT pathways have been demonstrated as the hallmarks in several primary and recurrent cancers. The strategy of concurrent blocking of these two pathways shows clinical merits on effective cancer therapy, such as combinatory treatments and dual-pathway inhibitors. Herein, we report a novel prototype of dual-pathway inhibitors by means of merging the core structural scaffolds of a MEK1 inhibitor and a PDK1 inhibitor.
View Article and Find Full Text PDFBackground. We aimed to investigate the distributive characteristics of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms and their influence on metformin efficacy in Chinese T2DM patients. Methods.
View Article and Find Full Text PDFAim: To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients.
Patients & Methods: 768 SNPs in or close to 207 genes were genotyped in 84 patients treated with metformin + glibenclamide/Xiaoke Pill. Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with metformin alone.